Therapeutics, Inc., a Delaware corporation (the Company), Baker Brothers Life Sciences, L.P. (BBLS) and 667, L.P. (667 and together with BBLS, the Investor). Terms of Submission BAKER BROTHERS LIFE SCIENCES, L.P. By: BAKER BROS. ADVISORS LP, management company and investment adviser to Baker Brothers Life Sciences, L.P., pursuant to authority granted to it by Baker Brothers Life Sciences Capital, L.P., general partner to Baker Brothers Life Sciences, L.P., and not as the general partner. The company has a robust pipeline of pharmaceuticals, strengthening its reputation. (j)Amendments and Waivers. Baker Brothers stake goes back to funding rounds prior to the IPO. Baker Brothers, a biotech investment firm, was founded by Julian & Felix Baker in 2000. The stock currently trades at ~$142. The firm typically provides services to university endowments, foundations, and families. There was a ~35% reduction last quarter at prices between ~$26 and ~$40.50. Baker Brothers, a biotech investment firm, was founded by Julian & Felix Baker in 2000. Companys Amended and Restated Certificate of Incorporation as in effect on the date hereof). I wrote this article myself, and it expresses my own opinions. By: /s/ Scott Lessing Additionally, Baker Bros. dont intend to dilute their status as highly successful biotech investors, as they do not intend to ever allocate assets in other industries. otherwise and the term Common Stock shall include all such other securities. Note: Baker Brothers controls ~26% of the business. There was a marginal increase this quarter. SEC form, multiple filers or classes of filers, and much more.***. (e)IPO means the Companys first underwritten public Note: 13F filing performance is different than fund performance. The increase happened at ~$72 per share. reserves the right to withhold any information and to exclude the Observer from any meeting or portion thereof that the (A)Board of Directors determines based upon the advice of outside counsel that (i)access to such information or Last major activity was in 2019 when Q2 to Q4 saw a roughly one-third selling at prices between ~$1.60 and ~$8.70. All remedies, either under this Agreement, or by law or otherwise afforded to any party, shall be cumulative and not alternative. The stock currently trades at ~$344 and the stake is at 1.48% of the portfolio. Shares started trading at ~$24 and currently goes for ~$246. The current minimum investment for Baker Brothers Life Sciences, L.P. is $40000000. (f)Purchase 14159 capital, l.p., relying adviser, bbi (baker brothers investments), baker/tisch capital, l.p., relying adviser, baker brothers life sciences capital, l.p . The stock currently trades at $71.81. Please send any feedback, corrections, or questions to support@suredividend.com. The stock is now at $87.22, and the stake is at 2.59% of the portfolio. The cookie is used to store the user consent for the cookies in the category "Performance". Retail investors should be wary of just copying the funds portfolio. Note: We do not offer technical support for developing or debugging scripted downloading processes. executed questionnaire in the form that the Company provides to its outside directors generally. from time to time. Performance & security by Cloudflare. The funds philosophy stands in holding its investments ordinarily for three years, though its higher-conviction investments can be seen held for longer. The fund owns around 16.3% of the company, with a market cap of $23 billion. Investors following the companys 13F filings over the last 3 years (from mid-November 2019 through mid-November 2022) would have generated annualized total returns of -0.82%. The funds strategy includes utilizing a fundamentally-driven way of investing to come up with its investment decisions, also known as bottom-up investing. Nonetheless, BeiGene produces miniature revenues against its $18.7 billion market cap, indicating that investors are betting heavily on the companys long-term prospects. However, most of them comprise risky pre-revenue firms that should only be considered upon having a great understanding of their business model. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users. The stock is now at $89.08. Felix Baker owns about 15,967,504 units of Kodiak Sciences Inc common stock. Subject to Section3(n) below, the provisions of this Agreement shall apply to the full extent set forth herein with respect to any and all shares of capitalstock of the Company or any successor or assign of the Company Last major activity in MRTX was a ~50% selling in Q3 2019 at prices between ~$76 and ~$106. Incyte Corporation focuses on the discovery, development, and commercialization of various therapeutics. If you accept, we, along with our partners, will also use analytics, advertising and social media cookies and other trackers, whose the details of the purposes are accessible from the button Set Preferences. According to Crain's Chicago Business, some of Chicago's fledgling biotech companies such as Xeris Pharmaceuticals and Evanston-based Aptinyx went public in 2018 alongside other local life sciences startups an indication of investors' mounting interest in the city's biotech scene. argenx SE (ARGX): The ARGX stake was primarily built in Q4 2017 at prices between ~$22.50 and ~$63. Ownership. Mr. Goller serves as a Partner of Baker Brothers Investments, a fund management company focused on long-term investments in life-sciences companies. You can email the site owner to let them know you were blocked. Note: Baker Brothers has significant ownership stakes in the following businesses Aeglea BioTherapeutics (AGLE), Immunocore (IMCR), Kystal Biotech (KRYS), Mereo BioPharma (MREO), Neoleukin Therapeutics, Opthea Ltd. (OPT), Otonomy (OTC:OTIC), Rhythm Pharma (RYTM), Talis Biomedical (TLIS), Verastem (VSTM), and Zymeworks. With respect to the Observer, the Companys obligations under this Section2(c) are contingent upon such Observers (x)entering into a confidentiality agreement with the Company in a form that is reasonably acceptable to the removed or otherwise fails to become or ceases to be a director for any reason, the Company shall cause the vacancy to be filled by the election or appointment of another Investor Designee nominated by the Investor as soon as reasonably practicable substantially the same time and in the same manner as provided to such directors; provided, however, that such Observer shall agree to hold in confidence all information so provided; and provided, further, that the Company Although there are ~120 positions in the 13F portfolio, the holdings are concentrated among a few large stakes. The Chicago area has 3.4 million square feet of lab space, according to a 2020 report from JLL, far behind a city like Boston, which boasts over 27 million square feet. The firm primarily invests in life science companies. Note: Baker Brothers controls ~5.5% of Amarin Corp. Seagen Inc. (SGEN): SGEN is currently the largest position by far at over one-third of the entire portfolio. IN WITNESS WHEREOF, each of the parties hereto has executed this Amended and Restated The Company shall notify the Investor of any objection to an Investor Designee pursuant to this Section2(b) sufficiently in advance of the date Baker Brothers Life Sciences Capital (GP) LLC New York, New York BlueMountain Capital Management Investment Management New York, NY . Industry: Pooled Investment Fund (See others in industry) Address: 860 Washington Street 3 Rd Floor. It is still a very small position at 0.80% of the portfolio. We reserve the right to block IP addresses that submit excessive requests. Youre viewing 5 of 7 investments. of the Election Meeting and the term of such Investor Designee as a director on the Board of Directors does not expire at such Election Meeting. [SIGNATURE PAGE TO TSCAN THERAPEUTICS AMENDED now or hereafter have to the venue of such action or proceeding in any such court or that such action or proceeding was brought in an inconvenient forum. In the event of any change in the capitalization of the Company, as a result of any stocksplit, stock dividend or stock combination or otherwise, Last significant activity was in Q4 2019 which saw a ~20% stake increase at prices between ~$14.50 and ~$76. the slate of nominees recommended to the Companys stockholders for election as directors of the Company an Investor Designee if the Investor already has at least one Investor Designee serving as a director on the Board of Directors at the time Council Members. Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. 33. Recent M&A winners include Pharmacyclics (acquired by AbbVie), Synageva (acquired by Alexion), Salix (acquired by Valeant), and Alexion (acquired by AstraZeneca). (f)Notice. (k)Jurisdiction. value remained steady this quarter at $22.77B. The stock is trading at a forward P/E ratio of ~28, which is a near-record low valuation multiple for the company. Your IP: Q4 2016 saw a stake doubling at prices between ~$28 and ~$36. Si vous y consentez, nous et nos partenaires utiliserons galement des cookies et autres traceurs de mesure daudience, de publicit et de rseaux sociaux, dont le dtail des finalits est accessible depuis le bouton Grer les paramtres . THIS AMENDED AND RESTATED NOMINATING AGREEMENT (this Agreement), dated as of April22, 2021, by and among TScan 151.252.56.27 These investors may include private investors, venture capital firms, or other investment vehicles. For more information, contact opendata@sec.gov. This is one of the funds highest conviction picks, as Baker Bros still owns nearly 26% of the companys shares, which have been held since 2010. inclusion in the Companys proxy materials for meetings of stockholders promptly after the Company requests such information from the Investor, and will cause the Investor Designee to submit on a timely basis to the Company a completed and [Remainder of page intentionally left blank]. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~64% of the portfolio. Agreement); WHEREAS, the Company and the Investor desire to amend and restate the Original Agreement pursuant to the terms and The cookies is used to store the user consent for the cookies in the category "Necessary". We give you the access and tools to invest like a Wall Street money manager at a Main Street price. Management owns 12 percent of the fund. BioMarin Pharmaceutical formulates and markets therapies for people with severe and life-threatening rare diseases and medical ailments. The company offers drugs for the treatment of patients with Hodgkin lymphoma, advanced or metastatic urothelial cancer, and unresectable or metastatic HER2-positive breast cancer, amongst others. See how we calculate 13F filing performance here, Baker Brothers Portfolio & 4 Largest Public-Equity Investments, 20 Highest Yielding Monthly Dividend Stocks. Angel, Fund of Funds, Venture Capital). Q1 2016 saw another ~20% stake increase at prices between ~$65 and ~$100. By using this site, you are agreeing to security monitoring and auditing. Assets under management grew from $250 million in 2003, to $15.2 billion as of November 15th, 2022. Is this happening to you frequently? Q3 2015 saw a ~30% stake increase at prices between ~$105 and ~$130. Nominating Agreement as of the date first above written. For the Baker Bros. -- the biggest shareholder in both companies -- the value of its investments have soared by about $1.4 billion. (b)Notwithstanding the provisions of Section2(a), the Investor shall not be entitled to designate any As Chicago's biotech ecosystem continues to expand . Despite the uncertainty surrounding BeiGene, the company has developed into a fully integrated global biotechnology company with operations in China, the United States, Europe, and Australia. If any provision of this Agreement shall be invalid, illegal or unenforceable, the After giving effect to the transactions reported herein and as a result of their ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Issuer's shares of Common Stock reported in column 5 of Table I directly held by Baker Brothers . Note: Baker Brothers controls ~13% of the business. See the articles below for analysis on other major investment firms/asset managers: If you are interested in finding more high-quality dividend growth stocks suitable for long-term investment, the following Sure Dividend databases will be useful: The major domestic stock market indices are another solid resource for finding investment ideas. There was a ~10% stake increase in Q1 2021 at prices between ~$268 and ~$380. NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy of which are I/we have a beneficial long position in the shares of ACAD, BMRN, INCY either through stock ownership, options, or other derivatives. (a)Subject at all times to Sections 2(b) and 3(n) below, during the period beginning immediately following the The stake had roughly doubled by 2006. The parties agree to use their best efforts and act in good faith in carrying out They have a ~29% ownership stake in the business. This is crucial when investing in the biotech industry, as each company is very unique, requiring niche knowledge to understand its business model. Baker Bros Advisors was founded in 2000 and is based in New York City. Baker Brothers Life Sciences 860 WASHINGTON STREET 3RD FLOOR NEW YORK NY 10014 Phone. Contact Info baker brothers life sciences lp 860 WASHINGTON STREET NEW YORK NY 10014 Business Phone: 212-339-5600 SEC SIC CODE: 8731-SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH Insider Information Trimeris Inc - Other Owner (06/22/2015) Xoma Corporation - Other Owner (07/22/2015) Genomic Health Inc - Director (10/01/2019) Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by Life Sciences, a Baker Brothers Life Sciences LP. There was a marginal increase last quarter. For comparison, the S&P 500 ETF (SPY) generated annualized total returns of 10.2% over the same time period. Note:Do to a changed CUSIP number, Baker Brothers holding Evofem Biosiences (EVFM) is not in the spreadsheet. Unlike many biotech companies, which are pre-revenue, Incyte has been growing its top and bottom line for years. San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. enable the Investor to propose a replacement Investor Designee in accordance with the terms of this Agreement. individual as a nominee to the Board of Directors if a majority of the disinterested members of the Board of Directors reasonably and in good faith determines, after consultation with the Companys outside legal counsel and upon written advice Signature and Submission Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice. To allow for equitable access to all users, SEC reserves the right to limit requests originating from undeclared automated tools. Note: Baker Brothers controls ~6% of the business. Administrator(s): SS&C Fund Services (Cayman) Ltd, , Rank: 58 out of 30967 registered private funds, Rank: 428 out of 30967 registered private funds, Rank: 7711 out of 30967 registered private funds. All notices required or permitted under this Agreement must be in writing and sent to the They add up to ~73% of the portfolio. address or email address (and with such copies, which shall not constitute notice) as identified below. While the fund has made great gains since, the recent plunge has definitely compressed its unrealized gains, as the position was held stable once again. to see more advanced email alert options such as selecting any type of Fewer than a dozen mutual funds are focused on life sciences, the largest of which are the T. Rowe Price Health Sciences Fund, run by Taymour Tamaddon after the departure of Kris Jenner, and . Except as otherwise provided herein, the provisions hereof shall inure to the Shares started trading at ~$20 and currently goes for $14.36. Heron Therapeutics (HRTX): HRTX is a 0.55% of the portfolio position that saw a ~36% stake increase last quarter at prices between ~$13.25 and ~$18.50. Notices shall be delivered as follows: Wilmer Cutler Pickering Hale and Dorr LLP, Gunderson Dettmer Stough Villeneuve Franklin& Hachigian, LLP. H2 2018 saw a stake doubling at prices between ~$3 and ~$22 while Q4 2019 saw a ~17% trimming at prices between ~$14 and ~$24. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD) It also develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer. Baker Bros owns around 25.5% of the company, the stock occupies around 38.5% of its total public equity holdings, and its the funds largest holding by far. Please declare your traffic by updating your user agent to include company specific information. Necessary cookies enable the website to function properly. Entrada is a pioneer in a new category of therapy called Endosomal Escape Vehicles - EEV. ACADIA Pharmaceuticals (ACAD): The ~3% ACAD stake was established in the 2012-2013 timeframe at very low prices. Keep reading this article to learn more about Baker Brothers Advisors. The life sciences sector is changing by the minute. Investor and its Affiliates, collectively, no longer beneficially own the Required Shares, the Company shall invite a designee of the Investor (the Observer) to attend all The stock currently trades at $3.46. Agreement. validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. It invests in the public equity markets of the United States. Active, Closed, This describes the type of investor this organization is (e.g. AND RESTATED NOMINATING AGREEMENT]. Instead, they emphasize that focusing on specific companies, which they can analyze and understand deeply and place concentrated positions in their securities, can generate superior returns over the long term. Positions that are between 0.10% and 0.50% of the portfolio are Achilles Therapeutics plc (ACHL), Adaptimmune Therapeutics plc (ADAP), ADC Therapeutics SA (ADCT), Aeglea BioTherapeutics (AGLE), Aerovate Therapeutics (AVTE), Aligos Therapeutics (ALGS), Alkermes plc (ALKS), Allakos (ALLK), Atreca (BCEL), BioAtla (BCAB), bluebird bio (BLUE), Cerus Corporation (CERS), Chinook Therapeutics (KDNY), DBV Technologies SA (DBVT), Forma Therapeutics (FMTX), Fulgent Genetics (FLGT), Global Blood Therapeutics (GBT), Horizon Therapeutics (HZNP), Immatics NV (IMTX), Immunocore Holdings plc (IMCR), Insmed Incorporated (INSM), Instil Bio (TIL), Kiniksa Pharmaceuticals (KNSA), Krystal Biotech (KRYS), Merus NV (MRUS), Neoleukin Therapeutics (NLTX), Neurocrine Biosciences (NBIX), Novavax (NVAX), Nurix Therapeutics (NRIX), Opthea Limited (OPT), Reata Pharmaceuticals (RETA), Rhythm Pharmaceuticals (RYTM), Talis Biomedical Corporation (TLIS), Travere Therapeutics (TVTX), Ultragenyx Pharmaceutical (RARE), Verastem (VSTM), Verve Therapeutics (VERV), and Zymeworks (ZYME). Recent activity follows. Julian has a business background from Harvard, while Felix has a Ph.D. in Immunology from Stanford. The parties also agree, without further consideration, to execute such further instruments and to take such further actions as may be necessary or desirable to carry out the purposes and intent of this See how we calculate 13F filing performance here. They had an IPO in November. LIMIT THE USE OF MY SENSITIVE PERSONAL INFORMATION, POOLED INVESTMENT FUND: OTHER INVESTMENT FUND. Please include what you were doing when this page came up and the Cloudflare Ray ID found at the bottom of this page. Companys shares are listed, the Bylaws or any policy, or guidelines previously approved by the Board of Directors, provided that a direct or indirect purpose of any such policy or guideline is not to obstruct the Investors right to Get the full list, Morningstar Institutional Equity Research. Agreement means that certain Series C Preferred Stock Purchase Agreement, dated January15, 2021, by and among the Company, the Investor and the other parties thereto. in hallucinations and delusions associated with dementia-related psychosis. Baker Brothers Life Sciences Capital, L.P. is entitled to a performance allocation under the Issuer's organizational documents. 1001 and 1030). Get the full list, Youre viewing 5 of 45 funds. Shares started trading at ~$25 and currently goes for ~$16. Sure Dividend compiles the following stock market databases and updates them monthly: Thanks for reading this article. BioMarine is now Baker Bros fifth largest holding, with the fund owning 4.14% of the companys outstanding shares. H1 2018 saw the stake built from ~3.8M shares to ~12M shares at prices between ~$100 and ~$215. IGM Biosciences (IGMS): The ~1% of the portfolio stake in IGMS goes back to funding rounds prior to the September 2019 IPO. Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features. 13F filing from Baker Brothers Life Sciences LP, enter your If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Notices shall be effective upon receipt. Shares started trading at ~$33 and currently goes for $11.43. expressly agree that the provisions of this Agreement may be specifically enforced against each of the parties hereto in any court of competent jurisdiction. Linda Rosenberg Ach P '12. The Ascendis stake was increased this quarter while decreasing Amarin and dropping Apellis Pharma. $0.0001 per share. this Agreement, to the jurisdiction of the courts of the United States located in the State of Delaware or in any Delaware state court and consent that any such action or proceeding may be brought in such courts and waive any objection that they may Additionally, the rights set forth in this Section2(c) may This analysis is for one-year following each trade, and . (b)Board of Directors means the Board of Directors of the Company. Broker-Dealer(s): Goldman, Sachs & Co., . This is a profile preview from the PitchBook Platform. As a percentage of AUM, allocation to the highest conviction picks can be very high at over 30%. It is a very long-term stake that has been in the portfolio for over fifteen years. Angel, Fund of Funds, Venture Capital), This describes the stage of investments made by this organization (e.g. Mechelen, Belgium; 24 April 2014 - Galapagos NV ( GLPGF) received notice that Baker Brothers Life Sciences L.P., 667 L.P. and 14159 L.P. currently collectively hold 4.99% of outstanding Galapagos. Mr. Goller serves as a Partner of Baker Brothers Investments, a fund management company focused on long-term investments in life-sciences companies. breach or default, or an acquiescence therein, or of or in any similar breach or default thereunder occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default therefore or thereafter occurring. Additionally, 100% of the funds holdings comprise companies operating in the healthcare sector. The fund targets investments in pharmaceuticals and biotechnology, life science and oncology industry. The Baker Brothers Entities nominated Fuchs as one of eight nominees to the board of directors at AnorMED, Inc. and, it can be inferred, given the timing, that Fuchs was also appointed by the Baker Brothers Entities to the Mirati Any waiver, permit, consent or approval of any kind or character on the part of the Investor of any breach or default of the Company under this Agreement, or any waiver on the part of any party of any provisions or conditions of this Agreement, in Investors that are familiar with biotech companies are likely to find some hidden gems amongst their holdings. This cookie is set by GDPR Cookie Consent plugin. Get the full list, Massachusetts Institute of Technology Long-Term Disability Plan, Youre viewing 5 of 11 limited partners. Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet. Sign-up AbCellera Biologics (ABCL): ABCL had an IPO in December 2020. Form D contains basic information about the offering and the company. Our clients include: large branded pharmaceutical companies established and emerging biotechnology companies international medical devices companies food and beverage companies Specializing in a sector that is challenging to understand by most investors, the firm has historically outperformed the overall market over several years, with its concentrated biotech portfolio. ACADIA Pharmaceuticals focuses on the development and commercialization of small molecule drugs aimed at unmet medical needs in central nervous system disorders. Note: Baker Brothers controls ~10% of Madrigal Sciences. DBV Technologies therapies are investigational and not FDA approved. The position was held stable during the quarter. It is based on Baker Brothers regulatory 13F Form filed on 11/15/2021. Felix Baker '91, PhD '98. Shares started trading at ~$10 and currently goes for $85.56. closing of the IPO and for three (3)years thereafter, at any time at which the Investor and its Affiliates, collectively, beneficially own (i)the Required Shares and (ii)at least 2% of the Companys then-outstanding voting Over the years, the firm had a number of home runs as the invested firms got acquired at huge premiums. Notices must be given: (a)by personal delivery, with receipt acknowledged; (b)by email followed by hard copy delivered by the methods They add up to ~73% of the portfolio. Baker Brothers Life Sciences LP; Firm: Fund # CIK # 0001363364: Sale: Fund: Phone: 2123395633: Address: 667 Madison Avenue New York, New York 10065: Source Fund structure AUM Fund type; Baker Brothers Investments: $25.71 bn: 667, L.P. $2.27 bn: Hedge Fund: Baker Brothers Life Sciences, L.P. $23.42 bn: Hedge Fund: Hcif Offshore LP: Latest filings (excl ownership) Julian & Felix Baker also separately own ~550K additional shares. The 2007-2008 timeframe saw the position increased from ~3.2M shares to ~11.1M shares at prices in the high single digits. All text and design is copyright 2020 WhaleWisdom.com. (c)Subject at all times to Section3(n) below and the other limitations set forth in this The stock is now well below that range at $9.78. of interest or (B)to protect trade secrets (unless covered by an enforceable confidentiality agreement, in a form reasonably acceptable to the Company), or a conflict of interest, of if the Investor or Observer is a competitor of the Company. The position was rebuilt in Q3 2019 at prices between ~$18.50 and ~$27. Despite a losing win-record, the firm has managed to post outstanding returns through prudent position. Custodian(s): Continental Stock Transfer & Trust Company, . Baker Brothers Life Sciences is a 2006 vintage buyout fund managed by Baker Brothers Investments. Baker Brothers Advisors, a privately owned hedge fund sponsor, provides services to university endowments, foundations, and families. Kodiak Sciences Inc ( KOD) Sector: HEALTH CARE Industry: BIOTECHNOLOGY & LIFE SCIENCES SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) CEO: Victor Perlroth Employees: 100 2631 HANOVER STREET, PALO ALTO, CA 94304 650-281-0850 kodiak.com Kodiak Sciences Inc. researches, develops, and commercializes therapeutics to treat retinal diseases.
Insight Partners Jerry Murdock Net Worth,
Places To Stop Between Nc And Florida,
Weslaco Isd Superintendent Suspended,
Arctic Fox Aquamarine And Violet Dream Mix,
Articles B